Search company, investor...


Founded Year




Total Raised


Date of IPO


About InventisBio

InventisBio (688382.SH) specializes in drug research and development, focusing on major diseases such as tumors and metabolic diseases. The company's products include inhibitor BPI-D0316, selective estrogen receptor degrader (SERD) D-0502, urate transporter 1 (URAT1) inhibitor D-0120, KRAS G12C inhibitor D-1553, and so on. The company was founded in 2013 and is based in Shanghai, China.

Headquarters Location

No. 63, Lane 1000, Zhangheng Road Pudong New Area

Shanghai, Shanghai,



Missing: InventisBio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: InventisBio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing InventisBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InventisBio is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

InventisBio Patents

InventisBio has filed 25 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics





Application Date


Grant Date



Related Topics



Latest InventisBio News

Inventisbio nets ¥2.084B in Shanghai IPO; shares plunge 15.6% on debut

Aug 2, 2022

Aug. 2, 2022 Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.

InventisBio Frequently Asked Questions (FAQ)

  • When was InventisBio founded?

    InventisBio was founded in 2013.

  • Where is InventisBio's headquarters?

    InventisBio's headquarters is located at No. 63, Lane 1000, Zhangheng Road, Shanghai.

  • What is InventisBio's latest funding round?

    InventisBio's latest funding round is IPO.

  • How much did InventisBio raise?

    InventisBio raised a total of $247M.

  • Who are the investors of InventisBio?

    Investors of InventisBio include Lilly Asia Ventures, OrbiMed Advisors, Advantech Capital, Pudong Innotec, CMB International Capital and 15 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.